Street renamed Healing Way ahead of Blood Cancer Healing Center’s opening
The University of Cincinnati Cancer Center announced the renaming of a street in anticipation of the opening of a new facility in Uptown Cincinnati. The Blood Cancer Healing Center, led by internationally known physician researcher John Byrd, will now be located on Healing Way.
"From the start of the cancer journey, it is important empathetic care leading to healing occurs,” said Byrd, MD, Cancer Center member and Gordon and Helen Hughes Taylor Professor and Chair of the Department of Internal Medicine at the UC College of Medicine. “This street will set the tone for those visiting the Blood Cancer Healing Center.”
The comprehensive Blood Cancer Healing Center will be an all-in-one facility dedicated solely to advancing research, treatment and wellness for patients with blood cancer.
Formerly called Shriners Way, Healing Way runs north and south between Albert Sabin Way and Goodman Avenue. The Blood Cancer Healing Center’s new address is now officially 3232 Healing Way, with the building also accessible off of Burnet Avenue.
Cancer Center leaders will celebrate the Blood Cancer Healing Center’s grand opening at a closed ceremony June 24, celebrating the beginning of clinical services, with research and other spaces within the facility scheduled to open in 2025. The event is not open to the public.
Featured photo at top of the street signs at the corner of Healing Way and Goodman Avenue. Photo/Abby Hardesty/UC Marketing + Brand.
Related Stories
Local 12, Business Courier highlight Blood Cancer Healing Center
February 19, 2024
Local 12 and the Cincinnati Business Courier highlighted the University of Cincinnati Cancer Center's Blood Cancer Healing Center, a comprehensive all-in-one facility dedicated solely to advancing research, treatment and wellness for blood cancer patients, opening this summer.
UC joining National Cancer Institute clinical trials network a 'big deal' for patients
October 17, 2023
The University of Cincinnati Cancer Center has joined the National Cancer Institute’s Experimental Therapeutics Clinical Trials Network (ETCTN), providing patients with access to cutting edge treatments only available through the network.
Pioneering new targeted treatments
June 10, 2022
The University of Cincinnati's Pier Paolo Scaglioni, MD, has received a $1.5 million National Cancer Institute grant to continue research into the roles of the KRAS gene and lipids in lung cancer.